Evaluation of cardiotoxicity using cardiac MRI in patients treated with IMRT and establishment of cardiac dose constraints

Evaluation of cardiotoxicity using cardiac MRI in patients treated with IMRT and establishment of cardiac dose constraints - Evaluation of cardiotoxicity using cardiac MRI in patients treated with IMRT and establishment of cardiac dose constraints

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049862

Enrollment

Registered

2022-12-26

Start date

2022-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer, lung cancer, malignant lymphoma

Interventions

Cardiac MRI examinations will be performed 3 times in total: before radiotherapy, 4 months after radiotherapy, and 1 year after radiotherapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance status 0-1, patients with written informed consent, patients for whom MRI examination can be safely performed

Exclusion criteria

Exclusion criteria: Patients with a history of ischemic heart disease, patients with abnormal signals of heart disease in cardiac MRI before radiotherapy, patients with a history of radiotherapy to the chest, patients with uncontrolled diabetes and hypertension

Design outcomes

Primary

Measure	Time frame
MR strain, Native T1	—

Countries

Japan

Contacts

Public ContactShintaro Tsuruoka

Ehime University Graduate School of Medicine Department of Radiology

tsuruoka.shintaro.az@ehime-u.ac.jp089-960-5371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026